Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ANL
Upturn stock ratingUpturn stock rating

Adlai Nortye Ltd. American Depositary Shares (ANL)

Upturn stock ratingUpturn stock rating
$1.47
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ANL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $9

1 Year Target Price $9

Analysts Price Target For last 52 week
$9Target price
Low$1.1
Current$1.47
high$4.1

Analysis of Past Performance

Type Stock
Historic Profit -44.84%
Avg. Invested days 21
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 57.20M USD
Price to earnings Ratio -
1Y Target Price 9
Price to earnings Ratio -
1Y Target Price 9
Volume (30-day avg) 1
Beta -
52 Weeks Range 1.10 - 4.10
Updated Date 06/30/2025
52 Weeks Range 1.10 - 4.10
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.62

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -1220.88%

Management Effectiveness

Return on Assets (TTM) -32.84%
Return on Equity (TTM) -103.19%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 23516104
Price to Sales(TTM) 29.48
Enterprise Value 23516104
Price to Sales(TTM) 29.48
Enterprise Value to Revenue 3.81
Enterprise Value to EBITDA -
Shares Outstanding 31236900
Shares Floating 59847067
Shares Outstanding 31236900
Shares Floating 59847067
Percent Insiders 14.25
Percent Institutions 0.18

Analyst Ratings

Rating 1
Target Price 9
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Adlai Nortye Ltd. American Depositary Shares

stock logo

Company Overview

overview logo History and Background

Adlai Nortye Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative oncology therapies. Founded in 2007, it aims to address unmet medical needs in cancer treatment.

business area logo Core Business Areas

  • Drug Development: Research and development of novel oncology drugs, focusing on innovative mechanisms of action.
  • Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates.
  • Commercialization: Bringing approved drugs to market and establishing commercial partnerships.

leadership logo Leadership and Structure

The leadership team comprises experienced executives in pharmaceutical research, development, and commercialization. The company structure includes research, clinical development, regulatory affairs, and commercial functions.

Top Products and Market Share

overview logo Key Offerings

  • AN2025 (buparlisib): A pan-PI3K inhibitor in clinical development for various cancers. It is currently in Phase III trials. Market share is not yet applicable as it's not approved. Competitors include other PI3K inhibitors from companies like Novartis and Bayer.
  • AN0025: A small molecule multi-kinase inhibitor in clinical trials. Market share is not yet applicable as it's not approved. Competitors include other multi-kinase inhibitors from companies like Pfizer and Bayer.

Market Dynamics

industry overview logo Industry Overview

The oncology drug market is large and growing, driven by increasing cancer incidence and advancements in treatment options. The industry is characterized by intense competition and high R&D costs.

Positioning

Adlai Nortye Ltd. aims to establish a competitive position through innovative drug candidates and strategic partnerships. Its advantage lies in its focus on novel mechanisms of action.

Total Addressable Market (TAM)

The global oncology market is estimated to reach over $300 billion in the coming years. Adlai Nortye Ltd. aims to capture a portion of this market with its pipeline of drug candidates.

Upturn SWOT Analysis

Strengths

  • Innovative drug pipeline
  • Experienced management team
  • Strategic partnerships
  • Focus on unmet medical needs

Weaknesses

  • High R&D costs
  • Dependence on clinical trial outcomes
  • Competition from established pharmaceutical companies
  • Limited commercial infrastructure

Opportunities

  • Expansion into new markets
  • Strategic acquisitions
  • Partnerships with larger pharmaceutical companies
  • Approval and commercialization of drug candidates

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from biosimilars
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • NVS
  • BAYRY
  • MRK

Competitive Landscape

Adlai Nortye Ltd. faces competition from established pharmaceutical companies with larger resources and broader product portfolios.

Growth Trajectory and Initiatives

Historical Growth: Growth trends depend on clinical trial progress and strategic partnerships.

Future Projections: Future growth depends on successful clinical trials and commercialization of drug candidates.

Recent Initiatives: Focus on advancing clinical trials and securing partnerships.

Summary

Adlai Nortye Ltd. is a biopharmaceutical company with a promising pipeline of oncology drugs and a focus on innovative mechanisms. Its success hinges on positive clinical trial results and the ability to secure strategic partnerships. High R&D costs and competition pose significant challenges. Securing funding will be important for continued growth and success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports

Disclaimers:

The data and analysis provided are based on publicly available information and industry reports. It should not be considered financial advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Adlai Nortye Ltd. American Depositary Shares

Exchange NASDAQ
Headquaters -
IPO Launch date 2023-09-29
Co- Founder, CEO & Chairman Mr. Yang Lu
Sector Healthcare
Industry Biotechnology
Full time employees 123
Full time employees 123

Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.